Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03497897 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT03497897 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT03497897, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
Interventions
- DRUG Placebo
- DRUG LYS006 20 mg
- DRUG LYS006 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03497897
The ClinicalTrials.gov registry entry for NCT03497897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03497897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03497897 about?
NCT03497897 is a clinical study titled "Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne". The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
What is the current status of trial NCT03497897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2018-09-10. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03497897?
The interventions under investigation include: Placebo (DRUG), LYS006 20 mg (DRUG), LYS006 2 mg (DRUG).
Who is sponsoring clinical trial NCT03497897?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.